Rigel Pharmaceuticals Inc (FRA:RI2) Stock Price, Trades & News

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	3.21
Equity-to-Asset	0.79
Debt-to-Equity	0.11
Debt-to-EBITDA	0.35
Interest Coverage	18.05
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.87	Distress Grey Safe
Beneish M-Score	1.6	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	30.3
	Future 3-5Y Total Revenue Growth Rate Estimate	14.13

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	36.86
	9-Day RSI	41.33
	14-Day RSI	46.33
	3-1 Month Momentum %	35.5
	6-1 Month Momentum %	17.45
	12-1 Month Momentum %	85.58

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.62
	Quick Ratio	2.48
	Cash Ratio	1.64
	Days Inventory	189.86
	Days Sales Outstanding	55.79
	Days Payable	98.6

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1.8
	Shareholder Yield %	1.31

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	93.39
	Operating Margin %	41.56
	Net Margin %	121.51
	EBITDA Margin %	43.79
	FCF Margin %	26.4
	OCF Margin %	26.4
	ROE %	180.4
	ROA %	110.81
	ROIC %	63.87
	3-Year ROIIC %	59.31
	ROC (Joel Greenblatt) %	755.61
	ROCE %	53.38
	Years of Profitability over Past 10-Year	2
	Moat Score	3
	Tariff Resilience Score	7

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	1.97
	Forward PE Ratio	11.9
	PE Ratio without NRI	1.97
	Price-to-Owner-Earnings	2.08
	PS Ratio	2.35
	PB Ratio	1.7
	Price-to-Tangible-Book	1.81
	Price-to-Free-Cash-Flow	8.85
	Price-to-Operating-Cash-Flow	8.85
	EV-to-EBIT	4.5
	EV-to-Forward-EBIT	6.74
	EV-to-EBITDA	4.42
	EV-to-Forward-EBITDA	6.74
	EV-to-Revenue	1.94
	EV-to-Forward-Revenue	2.08
	EV-to-FCF	7.32
	Price-to-GF-Value	1.32
	Price-to-Projected-FCF	3
	Price-to-Median-PS-Value	0.58
	Price-to-Graham-Number	0.4
	Price-to-Net-Current-Asset-Value	5.26
	Price-to-Net-Cash	16.21
	Earnings Yield (Greenblatt) %	22.22
	FCF Yield %	11.64

Financials (Next Earnings Date:2026-08-04)

Annual Quarterly TTM

FRA:RI2's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Rigel Pharmaceuticals Inc Executives

Details

GF Value™: €24.15

FRA:RI2

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with RI2. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	257.832
	EPS (TTM) (€)	16.032
	Beta	3.426
	3-Year Sharpe Ratio	0.73
	3-Year Sortino Ratio	1.7
	Volatility %	112.63
	14-Day RSI	46.33
	14-Day ATR (€)	0.900278
	20-Day SMA (€)	34.2925
	12-1 Month Momentum %	85.58
	52-Week Range (€)	17.8 - 43.4
	Shares Outstanding (Mil)	18.5

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Rigel Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Rigel Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-04 16:30	In 94 days
Third quarter earnings results for 2026	2026-11-04	In 93 days
Second quarter earnings conference call for 2026	2026-08-04 16:30	In 2 days
Second quarter earnings results for 2026	2026-08-04	In 1 day
Jefferies Global Healthcare Conference	2026-06-03 08:45	24.50 (-2.47%)
Guidance call for 2026	2026-05-19 09:30	24.34 (+0.00%)
General meeting for 2026	2026-05-14 07:30	26.73 (+8.70%)
First quarter earnings conference call for 2026	2026-05-05 16:30	24.97 (+1.30%)
First quarter earnings results for 2026	2026-05-05	24.97 (+1.30%)
Fourth quarter earnings conference call for 2025	2026-03-03 16:30	28.80 (+0.00%)

Show

Entries

Rigel Pharmaceuticals Inc Frequently Asked Questions

What is Rigel Pharmaceuticals Inc(FRA:RI2)'s stock price today?

The current price of FRA:RI2 is €31.93. The 52 week high of FRA:RI2 is €43.40 and 52 week low is €17.80.

When is next earnings date of Rigel Pharmaceuticals Inc(FRA:RI2)?

The next earnings date of Rigel Pharmaceuticals Inc(FRA:RI2) is 2026-08-04.

Does Rigel Pharmaceuticals Inc(FRA:RI2) pay dividends? If so, how much?

Rigel Pharmaceuticals Inc(FRA:RI2) does not pay dividend.

Press Release

	Subject	Date
	Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results	2026-07-28
	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	2026-07-07
	Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer	2026-07-01
	Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)	2026-06-16
	Rigel to Present at the Jefferies Global Healthcare Conference	2026-05-27
	Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress	2026-05-21
	Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference	2026-05-14
	Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer	2026-05-12
	Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results	2026-04-28
	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	2026-04-07

10/Page

Articles on Rigel Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.